Daito Pharmaceutical Co.,Ltd.
Символ: 4577.T
JPX
2502
JPYПазарна цена днес
12.0892
Съотношение P/E
-0.4771
Коефициент PEG
39.14B
MRK Cap
- 0.02%
Доходност на DIV
Daito Pharmaceutical Co.,Ltd. (4577-T) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 15979 | 3607 | 4381 | 3372.9 | |||||||||||||||
balance-sheet.row.short-term-investments | -205 | -205 | -206 | -294.2 | |||||||||||||||
balance-sheet.row.net-receivables | 51258 | 10670 | 10585 | 8382 | |||||||||||||||
balance-sheet.row.inventory | 78521 | 18238 | 16820 | 15751.7 | |||||||||||||||
balance-sheet.row.other-current-assets | 23816 | 8148 | 6123 | 4923.3 | |||||||||||||||
balance-sheet.row.total-current-assets | 169574 | 40663 | 37909 | 32429.9 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 108633 | 25837 | 23116 | 21372 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 1504 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1504 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.long-term-investments | 12388 | 3169 | 2958 | 3096 | |||||||||||||||
balance-sheet.row.tax-assets | -5690 | 504 | 570 | 508 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 7997 | 0 | -1 | 0.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 124832 | 29887 | 27029 | 25309.5 | |||||||||||||||
balance-sheet.row.other-assets | 3 | 2 | 1 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 294409 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.account-payables | 26111 | 4435 | 4493 | 4359.6 | |||||||||||||||
balance-sheet.row.short-term-debt | 7132 | 1513 | 1200 | 1375.1 | |||||||||||||||
balance-sheet.row.tax-payables | 1890 | 559 | 1402 | 1098.5 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 17400 | 3445 | 2247 | 2018.9 | |||||||||||||||
Deferred Revenue Non Current | 507 | 507 | 755 | 764.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 31 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 26505 | 4101 | 3887 | 3399.9 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 21030 | 4153 | 3199 | 2963.2 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 92 | 92 | 0 | 1.5 | |||||||||||||||
balance-sheet.row.total-liab | 87940 | 19581 | 17268 | 15822 | |||||||||||||||
balance-sheet.row.preferred-stock | 49141 | 49141 | 46273 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 28744 | 7186 | 7031 | 6271.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 142520 | 35006 | 32338 | 28331.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 6322 | 1531 | 1031 | 872.4 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -21341 | -42192 | -39369 | 6143.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 205386 | 50672 | 47304 | 41619 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 294408 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.minority-interest | 1082 | 299 | 367 | 298.4 | |||||||||||||||
balance-sheet.row.total-equity | 206468 | 50971 | 47671 | 41917.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 294408 | - | - | - | |||||||||||||||
Total Investments | 12183 | 2964 | 2752 | 2801.8 | |||||||||||||||
balance-sheet.row.total-debt | 24532 | 4958 | 3447 | 3394 | |||||||||||||||
balance-sheet.row.net-debt | 8553 | 1351 | -934 | 21.1 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3279 | 5076 | 6720 | 5873.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 2716 | 3870 | 3313 | 3154.3 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -2326 | -4399 | -1582.4 | |||||||||||||||
cash-flows.row.account-receivables | 0 | -1502 | -3299 | 2723 | |||||||||||||||
cash-flows.row.inventory | 0 | -1413 | -1041 | -3609.2 | |||||||||||||||
cash-flows.row.account-payables | 0 | 538 | 22 | -765.1 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 51 | -81 | 69 | |||||||||||||||
cash-flows.row.other-non-cash-items | -3279 | -2465 | -1264 | -2263.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5432 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 68 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -68 | 0 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 256 | 5 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | -10 | 77 | 20.3 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -5566 | -4400 | -6324.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -1638 | -1444 | -1712.4 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 308 | 1514 | 1798.5 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -116 | 1499 | -0.3 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -931 | -660 | -658.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2993 | 80 | 1997 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 616 | 989 | 1424.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 20 | 48 | 5.8 | |||||||||||||||
cash-flows.row.net-change-in-cash | 943 | -774 | 1009 | 288.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 12194 | 3607 | 4381 | 3372.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 11251 | 4381 | 3372 | 3084.1 | |||||||||||||||
cash-flows.row.operating-cash-flow | 5432 | 4155 | 4370 | 5182.5 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 5432 | -1401 | -363 | -1167 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 45193 | 45101 | 43464 | 48709.2 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 35529 | 34770 | 32005 | 37917.3 | |||||||||||||||
income-statement-row.row.gross-profit | 9664 | 10331 | 11459 | 10791.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 3591 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 4 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 5457 | 5123 | 4905 | 4883.1 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 40986 | 39893 | 36910 | 42800.3 | |||||||||||||||
income-statement-row.row.interest-income | 26 | 45 | 46 | 0.4 | |||||||||||||||
income-statement-row.row.interest-expense | 23 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 311 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 4 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 311 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.interest-expense | 23 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1889.5 | 3870 | 3313 | 3154.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 5115 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 4205 | 5207 | 6553 | 5908.8 | |||||||||||||||
income-statement-row.row.income-before-tax | 4520 | 5076 | 6720 | 5873.9 | |||||||||||||||
income-statement-row.row.income-tax-expense | 1343 | 1549 | 2092 | 1716.9 | |||||||||||||||
income-statement-row.row.net-income | 3279 | 3600 | 4668 | 4246 |
Често задавани въпроси
Какво е Daito Pharmaceutical Co.,Ltd. (4577.T) общи активи?
Daito Pharmaceutical Co.,Ltd. (4577.T) общите активи са 70552000000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 22484000000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 346.005.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 346.005.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.073.
Какъв е общият приход на предприятието?
Общият приход е 0.093.
Каква е Daito Pharmaceutical Co.,Ltd. (4577.T) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 3600000000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 4958000000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 5123000000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 3785000000.000.